Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

This study has been completed.
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland Identifier:
First received: May 13, 2005
Last updated: July 1, 2015
Last verified: July 2015